Cerebrospinal fluid: A specific biofluid for the biosensing of Alzheimer's diseases biomarkers

Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder with an irreversible, progressive, and untreatable nature that causes progressive deterioration, loss of neurons, and cognitive and behavioral decline. An exponential growth of AD is expected in the forthcoming decades. Studies show that amyloid b (Ab) and Tau proteins are two key biomarkers of AD. Abnormality in Ab and Tau levels in biofluids - especially cerebrospinal fluid (CSF) - is directly related to AD incidence and progress. Hence, developing sensitive, affordable, and reliable methods for screening and evaluating these biomarker levels is helpful in early diagnosis, tracking, and treatment of AD. This article scrutinizes the possible effect of Alzheimer's condition on CSF. Following a comprehensive summary of biosensors, the latest developed biosensors are discussed for the detection of Ab and Tau in CSF samples. & COPY; 2023 Elsevier B.V. All rights reserved.